Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Translate Bio, Inc. (TBIO)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | GlobeNewsWire
a week ago | The Motley Fool
a week ago | PRNewsWire
a week ago | Business Wire
2 weeks ago | Zacks Investment Research
2 weeks ago | Benzinga
a month ago | GlobeNewsWire
2 months ago | GlobeNewsWire
2 months ago | GlobeNewsWire
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.